CPT code 78075 denotes a nuclear medicine functional adrenal imaging study that evaluates and identifies abnormal adrenal function using an intravenous radiolabeled cholesterol or radioactive tracer with delayed imaging performed three to seven days after injection. The test is clinically important for diagnosing adrenal disorders such as hormonally active adenomas or hyperplasia and can influence surgical and medical management decisions across the country. Nationally, this imaging modality is a specialized diagnostic tool utilized by endocrinologists, nuclear medicine physicians, and radiology practices.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarking context for utilization and payment where available, an overview of clinical indications and procedural logistics, and a summary of common modifiers and administrative considerations used with this code. The publication also outlines typical sites of service and service components (tracer injection, patient preparation, delayed imaging, and medication coordination).

This summary provides clinicians, coding professionals, and payers with an at-a-glance understanding of the procedure represented by CPT code 78075, its clinical role, and the administrative elements relevant to billing and scheduling. Data not available in the input is identified explicitly where applicable in the full publication.